PLSE NASDAQ
Pulse Biosciences, Inc.
1W: -5.7%
1M: +4.6%
3M: +19.3%
YTD: +90.9%
1Y: +49.7%
3Y: +222.7%
5Y: +46.5%
$25.89
+0.33 (+1.29%)
Weekly Expected Move ±15.9%
$17
$21
$25
$28
$32
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (84)
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization - AD HOC NEWS
[SCHEDULE 13D/A] PULSE BIOSCIENCES, INC. Amended Major Shareholder Report - Stock Titan
Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus
Pulse Biosciences (PLSE) Stock Soars After Insider Buying - GuruFocus
Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - MEXC
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - MEXC
Pulse Biosciences (PLSE) Co-Chairmen Invest $13.3M in Company St - GuruFocus
Pulse Biosciences (PLSE) Stock Surges 17% on Major $13M Insider Purchase - Blockonomi
Pulse Biosciences (PLSE) Stock Jumps 17% After $13M Insider Buy - CoinCentral
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com Nigeria
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com
Pulse Biosciences stock jumps after insiders buy $13.3M in shares - Investing.com
Pulse Biosciences Co-Chairmen Purchase $13.3 Million in Company Stock - citybiz
Pulse Biosciences insiders buy $13.3 million in stock By Investing.com - Investing.com Australia
$13.3M insider stock buy: Pulse Biosciences chiefs add 675K shares - Stock Titan
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million - Yahoo Finance
Pulse Biosciences (NASDAQ: PLSE) CEO adds 15,000 shares in open-market buy - Stock Titan
Pulse Biosciences CEO Paul Laviolette buys $295,350 in company stock By Investing.com - Investing.com South Africa
Pulse Biosciences CEO Paul Laviolette buys $295,350 in company stock By Investing.com - Investing.com Nigeria
Pulse Biosciences director Robert Duggan buys $13 million in shares By Investing.com - Investing.com Nigeria
Pulse Biosciences 10% Owner Purchased Shares Worth Over $12M - TradingView
Pulse Biosciences director Robert Duggan buys $13 million in shares - Investing.com
[Form 4] PULSE BIOSCIENCES, INC. Insider Trading Activity - Stock Titan
Robert Duggan adds 660K Pulse Biosciences (PLSE) shares in open-market buy - Stock Titan
Major holder controls 71.6% as Pulse Biosciences (NASDAQ: PLSE) outlines 2026 vote - Stock Titan
PLUS Stock Price, Quote & Chart | EPLUS INC (NASDAQ:PLUS) - ChartMill
Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?
Pulse Biosciences Q1 Earnings Call Highlights
PLSE Q1 2026 Earnings Transcript
PLSE Q1 2026 Earnings Transcript
Pulse Biosciences to webcast May 13 presentation from BofA conference - Stock Titan
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo! Finance Canada
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase
Pulse Biosciences (PLSE) Q1 2025 Earnings Transcript
PLSE Q4 2025 Earnings Transcript
PLSE Q4 2025 Earnings Transcript
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Earnings Scheduled For May 4, 2026
Pulse Biosciences GAAP EPS of -$0.27 beats by $0.05, revenue of $0.4M in-line
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences Trials And Conference Spotlight Reframe Pulse Field Ablation Story
Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
Pulse Biosciences to Host Analyst Event on April 25, 2026
Argo Wealth Advisory LLC Makes New $387,000 Investment in Pulse Biosciences, Inc $PLSE
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy?
Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings
Pulse Biosciences hires Liane Teplitsky as COO
Pulse Biosciences Strengthens Executive Leadership Team
12 Health Care Stocks Moving In Tuesday's Intraday Session
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
$PLSE stock is down 13% today. Here's what we see in our data. - Quiver Quantitative
Pulse Biosciences Stock Drops 13% In A Day, Why You Shouldn Not Be Buying The Stock - Trefis
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences to accelerate Pulse Cardiac Catheter Ablation System
Pulse Biosciences slips despite Q4 beat after deal to sell shares
Pulse Biosciences targets CE Mark submission in 2026 as nPulse platform advances clinical milestones
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
What's Going With Pulse Biosciences Stock On Monday?
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Here’s Why
Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026
Pulse Biosciences' nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology
Critical Contrast: Pulse Biosciences (NASDAQ:PLSE) vs. ENDRA Life Sciences (NASDAQ:NDRA)
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)